CA2354189A1 - Methods of inhibiting ectopic calcification - Google Patents

Methods of inhibiting ectopic calcification Download PDF

Info

Publication number
CA2354189A1
CA2354189A1 CA002354189A CA2354189A CA2354189A1 CA 2354189 A1 CA2354189 A1 CA 2354189A1 CA 002354189 A CA002354189 A CA 002354189A CA 2354189 A CA2354189 A CA 2354189A CA 2354189 A1 CA2354189 A1 CA 2354189A1
Authority
CA
Canada
Prior art keywords
osteopontin
ectopic calcification
calcification
cells
ectopic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002354189A
Other languages
English (en)
French (fr)
Inventor
Cecilia M. Giachelli
Susie Steitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2354189A1 publication Critical patent/CA2354189A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002354189A 1998-12-07 1999-12-07 Methods of inhibiting ectopic calcification Abandoned CA2354189A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/206,576 US6551990B2 (en) 1998-12-07 1998-12-07 Methods of inhibiting ectopic calcification
US09/206,576 1998-12-07
PCT/US1999/029173 WO2000033865A1 (en) 1998-12-07 1999-12-07 Methods of inhibiting ectopic calcification

Publications (1)

Publication Number Publication Date
CA2354189A1 true CA2354189A1 (en) 2000-06-15

Family

ID=22766997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002354189A Abandoned CA2354189A1 (en) 1998-12-07 1999-12-07 Methods of inhibiting ectopic calcification

Country Status (6)

Country Link
US (2) US6551990B2 (https=)
EP (1) EP1135155A1 (https=)
JP (1) JP2002531517A (https=)
AU (1) AU769806B2 (https=)
CA (1) CA2354189A1 (https=)
WO (1) WO2000033865A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295010A1 (en) * 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
AU2003239589A1 (en) * 2002-05-24 2003-12-12 Schering-Plough Ltd. Eta-1 gene and methods for use
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
CA2547654C (en) * 2003-12-01 2012-09-25 Arla Foods Amba Use of osteopontin in dental formulations
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US7167746B2 (en) 2004-07-12 2007-01-23 Ats Medical, Inc. Anti-coagulation and demineralization system for conductive medical devices
US20060276534A1 (en) * 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification
US7463758B2 (en) * 2005-06-02 2008-12-09 Nordio Bioscience A/S Method of deriving a quantitative measure of a degree of calcification of an aorta
US7561727B2 (en) * 2005-06-02 2009-07-14 Nordic Bioscience Imaging A/S Method of deriving a quantitative measure of a degree of calcification of an aorta
JP5199077B2 (ja) * 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
US20070005213A1 (en) * 2005-06-30 2007-01-04 Hyundai Autonet Co., Ltd. Backward control for automobiles using telematics and method thereof
US20070134229A1 (en) * 2005-10-11 2007-06-14 Bin Tian Non-native constitutively active osteopontin
AU2006304778B2 (en) * 2005-10-21 2011-04-28 Amgen Inc. Methods of decreasing vascular calcification using IL-1 inhibitors
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
AU2008223817A1 (en) * 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
WO2008137281A1 (en) * 2007-05-03 2008-11-13 Fox Chase Cancer Center Compositions and methods for altering pancreas or liver function
JP5339748B2 (ja) * 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット.オー.オー. 神経膠腫を治療するための組成物および方法
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
WO2014071128A1 (en) * 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Macrophage-derived matrix vesicles: an alternative mechanism for microcalcification in atherosclerotic plaques
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
DK3618845T3 (da) 2017-05-04 2021-04-19 Follicum Ab Peptider til behandling af diabetes
CN109557309B (zh) * 2018-12-04 2021-09-10 九江学院附属医院 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001350A (en) * 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
US5304496A (en) 1991-06-10 1994-04-19 Children's Hospital Of Philadelphia Biological regulation of mineralization
WO1994025584A1 (en) * 1993-04-28 1994-11-10 Johns Hopkins University School Of Medicine Chronic endothelial cell culture under flow
US5824651A (en) 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
US5695761A (en) 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta

Also Published As

Publication number Publication date
AU2478300A (en) 2000-06-26
WO2000033865A9 (en) 2002-08-22
WO2000033865A1 (en) 2000-06-15
US20030158113A1 (en) 2003-08-21
JP2002531517A (ja) 2002-09-24
WO2000033865A8 (en) 2003-11-06
US20020032157A1 (en) 2002-03-14
AU769806B2 (en) 2004-02-05
EP1135155A1 (en) 2001-09-26
US7419950B2 (en) 2008-09-02
US6551990B2 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
AU769806B2 (en) Methods of inhibiting ectopic calcification
JP2002531517A5 (https=)
JP3693338B2 (ja) 組織形成因子誘導による炎症反応の調節
Riches The multiple roles of macrophages in wound healing
Yeh et al. Soluble lumican glycoprotein purified from human amniotic membrane promotes corneal epithelial wound healing
JP3973050B2 (ja) モルフォゲン誘発性肝再生
US20080267924A1 (en) Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US5849686A (en) Morphogen-induced liver regeneration
US20100041605A1 (en) Use of VEGF-C or VEGF-D in Reconstructive Surgery
JP2002506008A (ja) 血管新生を調整するための組成物及び方法
Schissel et al. Aortic carboxypeptidase-like protein is expressed in fibrotic human lung and its absence protects against bleomycin-induced lung fibrosis
EP2310035B1 (en) Fibroblast growth factor (fgf) analogs and uses thereof
Birinyi et al. Observations on human smooth muscle cell cultures from hyperplastic lesions of prosthetic bypass grafts: Production of a platelet-derived growth factor—like mitogen and expression of a gene for a platelet-derived growth factor receptor—A preliminary study
Masaie et al. Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates
Sweetwyne et al. The calreticulin-binding sequence of thrombospondin 1 regulates collagen expression and organization during tissue remodeling
WO2010027802A2 (en) Methods for treating diabetic wounds
Choi et al. Olfactory neuroblastoma: an immuno-electron microscopic study of S-100 protein-positive cells
US6413931B1 (en) Peptide inhibitor of fibrinogen blood clotting
EP1557174A1 (en) Composition containing eosinophil cationic protein
WO1997044059A2 (en) Cartilage type ii collagen as an angiogenic factor
Liu et al. Integrating Untargeted Metabolomics Revealed Ferulic Acid Treatment on Endothelial Progenitor Cells Mediated Vascular Dysfunction Following Diabetic Wound
Atria Understanding the Role of Skeletal Stem Cells in Load-Induced Bone Formation, Bone Repair, and Their Relationship With Angiogenesis
Kricker Structural investigations into the relationships of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) with vitronectin (VN)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued